August 17, 2018
Facilitating Drug Discovery with 3D In Vitro Oncology Models
Around 95% of new anticancer drugs eventually fail in clinical trials, despite promising results when tested on 2D in vitro preclinical models. New models that better mimic tumor biology in vivo can facilitate more efficient and translatable drug discovery research.
LEARN MORE
August 7, 2018
Preclinical Research Models of NAFLD/NASH
Most preclinical models of NAFLD/NASH are limited to studying specific aspects of the disease. In this blog post, you ...
LEARN MORE
August 2, 2018
Are Noninvasive Tests Enough for NAFLD/NASH Diagnosis?
There is significant interest in validating strategies for the noninvasive evaluation of fibrosis in NAFLD/NASH. This ...
LEARN MORE
July 31, 2018
From Pathogenesis to Treatment with NAFLD/NASH
Non-alcoholic steatohepatitis (NASH) is a hot topic in 2018, with a race to the first approved treatment well under way ...
LEARN MORE
July 26, 2018
IDO to I DON’T – IDO1 Inhibitor Development News
As targeted immuno-oncology agents make impressive strides in cancer treatment, researchers are looking for agents that ...
LEARN MORE
July 24, 2018
Improving Cardiac Function with FTY720 – ADA 2018
Our ADA presentations this year included a collaborative poster with Pegasus Bio. The studies used our unique panel of ...
LEARN MORE
July 19, 2018
Connecting Inflammation, Diabetes, and Obesity
We presented data on our next generation type 2 diabetes (T2D) and obesity rodent models at the ADA Scientific Sessions this year. This included the latest research using the FATZO mouse investigating whether murine models can be used to understand underlying inflammatory mechanisms as they relate to T2D and obesity.
LEARN MORE
July 17, 2018
Cardiomyopathy Treatment in Rodent Models – ADA 2018
At ADA 2018, we shared the latest data on our next generation type 2 diabetes (T2D) and obesity rodent models. This ...
LEARN MORE
July 5, 2018
Personalized Cancer Immunotherapy
Precision medicine and immunotherapy are currently two of the hottest areas of cancer research. How can immuno-oncology ...
LEARN MORE
July 3, 2018
Custom Murine Tumor Homografts for Efficacy Assessment
Murine tumor homografts provide an immunotherapeutic efficacy testing platform with the strengths of GEMM paired with ...
LEARN MORE
June 28, 2018
Assessing Combination Therapies in Syngeneic Tumor Models
Combination immunotherapy could enhance the clinical benefits of monotherapies and overcome patient lack of response to these novel agents. This means assessing a wide range of potential combinations, and syngeneic tumor models provide an ideal evaluation platform.
LEARN MORE
June 26, 2018
Why to Use Isotype Control Antibodies
Good experimental design is key to accurate and precise drug development. Isotype control antibodies, designed and ...
LEARN MORE
June 21, 2018
Immunocompetent Murine Models for Immunotherapy Assessment
Immunocompetent models are necessary for the preclinical assessment of novel immunotherapies, but multiple murine model ...
LEARN MORE
June 19, 2018
DGAT2 Inhibition Doesn’t Affect Plasma Triglycerides, VLDL ApoB
In a new study published in Cell Metabolism, McClaren et al utilize a variety of translational models, including both ...
LEARN MORE
June 15, 2018
Mouse Models of Multiple Sclerosis
Multiple sclerosis is a chronic disease affecting the central nervous system, which has multiple stages and currently ...
LEARN MORE
